Investor
Relations

Spero Therapeutics is advancing third-generation immunology and inflammation medicines, bringing better options to patients who need them most.

Who we are

Company Overview

Spero Therapeutics is a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation for patients with serious diseases and major treatment gaps. The company’s lead program, SP001, is a novel, Fc-silent anti-CD40L monoclonal antibody being advanced in IgG4-related disease, with broader potential for additional immune-related conditions.

Stock Information